euro-biopharma-ethnopharmacology-2017-tracks

25 / 28

Notes:
Volume 6, Issue 4 (Suppl) Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 49
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6th International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4th EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Oral booster vaccine against hepatitis B in the form of low-dosed lyophilised plant tissue bearing S-HBsAg
VLPs
Marcin Pyrski1, Marcin Czyż1 , Radosław Dembczyński2, Roman Marecik2, Magdalena Milczarek3, Elżbieta Pajtasz-Piasecka 3, Justyna Wojas-Turek3, Joanna
Wietrzyk3 and Tomasz Pniewski 1
1Institute of Plant Genetics - Polish Academy of Sciences, Poland
2Poznań University of Life Sciences, Poland
3Institute of Immunology and Experimental Therapy - Polish Academy of Sciences, Poland
The continued HBV high prevalence coupled with deficiencies in vaccination programmes stimulate research on a new type
of vaccines. Potential orally administered plant-based vaccine is highly attractive regarding efficacy, cost-effectiveness and
availability of mass hepatitis B prevention. Freeze-dried oral formulations facilitate elimination of complex purification steps, size
reduction and better stability during storage, as well as ensure controlled administration regime in minimised medical facilities.
Micropropagation of lettuce expressing S-HBsAg was optimised to provide repeatable uniform feedstock for plant-derived oral
vaccine manufacturing. Lyophilisation protocol facilitating successful processing of lettuce leaf tissue containing S-HBsAg assembled
into VLPs (Virus-Like Particles) was developed. Several drying profiles and excipients as well as effects of freezing rate and post-
process residual moisture were analysed. The profile of 20ºC for 20 h for primary and 22ºC for 2 h for secondary drying as well as
sucrose proved the most efficient stabilisation of S-HBsAg during freeze-drying. The process was highly reproducible (86-97%), and
provided a product with VLP content up to 200 µg/g DW. Atmosphere of nitrogen proved to preserve S-HBsAg VLPs for minimum
one year at temperatures up to 37°C. Low-dosed (5-200 ng) preparation used as oral booster vaccine elicited anti-HBs response in
animals at level of commercial injection vaccine (around 1000 mIU/ml). As a result, a plant-derived semi-product with good long-
term stability and immunogenicity of S-HBsAg was obtained for the definite formulation of oral booster vaccine against HBV.
Biography
Marcin Pyrski is a PhD student in Bioengineering Team led by Dr. Tomasz Pniewski in the Institute of Plant Genetics, PAS. He completed Engineering and Master’s
degrees in Biotechnology at the University of Life Sciences in Poznań. He had attended one year training in plant micropropagation in Floralab Company. Actually
he is working with plant-based HBV antigens on their expression, functionality and immunogenicity.
Marcin Pyrski et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-025